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Abstract
An increase in apoptotic events may underlie neuropathology in schizophrenia. By data-mining approaches, we identified
significant expression changes in death receptor signaling pathways in the dorsolateral prefrontal cortex (DLPFC) of patients
with schizophrenia, particularly implicating the Tumor Necrosis Factor Superfamily member 6 (FAS) receptor and the Tumor
Necrosis Factor [ligand] Superfamily member 13 (TNFSF13) in schizophrenia. We sought to confirm and replicate in an
independent tissue collection the noted mRNA changes with quantitative real-time RT-PCR. To test for regional and
diagnostic specificity, tissue from orbital frontal cortex (OFC) was examined and a bipolar disorder group included. In
schizophrenia, we confirmed and replicated significantly increased expression of TNFSF13 mRNA in the DLPFC. Also, a
significantly larger proportion of subjects in the schizophrenia group had elevated FAS receptor expression in the DLPFC
relative to unaffected controls. These changes were not observed in the bipolar disorder group. In the OFC, there were no
significant differences in TNFSF13 or FAS receptor mRNA expression. Decreases in BH3 interacting domain death agonist
(BID) mRNA transcript levels were found in the schizophrenia and bipolar disorder groups affecting both the DLPFC and the
OFC. We tested if TNFSF13 mRNA expression correlated with neuronal mRNAs in the DLPFC, and found significant negative
correlations with interneuron markers, parvalbumin and somatostatin, and a positive correlation with PPP1R9B (spinophilin),
but not DLG4 (PSD-95). The expression of TNFSF13 mRNA in DLPFC correlated negatively with tissue pH, but decreasing pH
in cultured cells did not cause increased TNFSF13 mRNA nor did exogenous TNFSF13 decrease pH. We concluded that
increased TNFSF13 expression may be one of several cell-death cytokine abnormalities that contribute to the observed
brain pathology in schizophrenia, and while increased TNFSF13 may be associated with lower brain pH, the change is not
necessarily causally related to brain pH.
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Introduction
Apoptosis is a cell death mechanism that can be triggered by
normal developmental events or by extrinsic factors. Unbiased
genome-wide analyses have implicated apoptotic pathways in the
genetics of schizophrenia [1]. Other studies have linked polymor-
phisms and brain expression changes in apoptotic signaling genes
to decreased calbindin-positive interneuron density and decreased
number of perineuronal oligodendrocytes in schizophrenia [2–4].
Furthermore, an increased ratio of pro-apoptotic BAX to anti-
apoptotic BCL-2 protein in the dorsolateral prefrontal cortex
(DLPFC) from patients compared with controls suggests a bias
favoring cell death processes in schizophrenia [5]. However, in this
previous study there was no evidence for increased apoptosis in
schizophrenia, as levels of the central apoptotic effector protease,
caspase 3, were not changed [5]. The results of two other studies
were also inconsistent with increased cell death. Reduced levels of
the pro-apoptotic mitochondrial protein, Septin 4, and reduced
density of apoptotic cells were found in DLPFC of people with
schizophrenia [6]. Benes and colleagues [7] found fewer apoptotic
cells in the anterior cingulate cortex in schizophrenia. Together
these findings suggest apoptotic signaling may be altered in
schizophrenia. However, it remains unclear whether cell death
effectors are increased or decreased, and a direct link between
apoptotic signaling and indices of cortical pathology has not been
established.
Large changes in neuronal numbers, as would be predicted
from ubiquitously altered apoptotic signaling, are not a core
feature of schizophrenia [8,9]. Rather neuronal density may be
increased [10,11] along with a reduction in somal size of neurons
[12–17]. Therefore, if increased apoptotic signaling is etiologically
involved in schizophrenia, presumably it may have more subtle
effects on regression of subcellular components, such as dendritic
spines, rather than cell death per se. Alternatively, increased cell
death could affect a relatively small subset of neurons. Indeed,
recent evidence suggests that certain types of cortical interneurons
may be more susceptible to cell damage or death, such as fast-
spiking parvalbumin [18] or layer II interneurons [19]. Currently,
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relate to the neuropathology found in two main cortical neuron
populations, pyramidal cells and inhibitory interneurons, in
schizophrenia.
In pyramidal neurons, schizophrenia pathology includes
reduced dendritic fields [20–22] and loss of dendritic spines [23–
25] affecting layer III across several cortical regions, but most
commonly investigated in the DLPFC. Although pyramidal cell
changes in schizophrenia may be secondary to a number of other
processes [26], dendritic changes could be primary and result in
neural system dysfunction. As reduced dendritic spine density has
been directly linked to reduced excitatory inputs onto pyramidal
neurons [27], it may account for a deficit in glutamatergic function
in schizophrenia [28]. A possible explanation for reduced spine
numbers in schizophrenia is increased localized apoptotic
signaling in dendrites that results in retraction of spines [29,30].
One of the most consistent findings in schizophrenia neuropa-
thology is deficits in cortical inhibitory interneurons across
multiple cortical regions [31,32], though most commonly reported
in DLPFC. Specifically, findings include reduced expression of the
GABA-synthesizing enzyme glutamate decarboxylase 1, 67 kDa
isoform (GAD67), which has recently been reviewed [33], reduced
expression of the calcium binding protein parvalbumin [31,34–
41], and reduced expression of the neuromodulator peptide
somatostatin [31,37,41,42]. These interneuron-specific deficits
could be primary or secondary due to reduced excitatory drive
from pyramidal neurons [26]. One of the leading models of
schizophrenia is based on the psychotomimetic effects of non-
competitive antagonists of the N-methyl-D-aspartate (NMDA)
receptor. Phencyclidine, ketamine and MK-801 block interneuron
function in proportion to their NMDA blocking potency [43].
While the data to support altered rates of cell death of interneuron
subtypes in cortex from patients with schizophrenia are lacking
[44], a study of gene expression in hippocampal interneurons has
implicated the apoptosis-related cell cycle regulator histone
deacetylase 1 in this disease [45,46]. Since many different ligands,
receptors and effectors are involved in regulating cell death [47]
we took a broad approach to surveying multiple cell death
transcripts that might be involved in schizophrenia in order to
identify a specific cell death pathway for more in-depth analysis.
In the current study, we explored the microarray database from
the Stanley Medical Research Institute (SMRI) Array postmortem
brain tissue collection [48] as a first step to identify apoptotic
pathways with altered gene expression in the DLPFC from
patients with schizophrenia. Significant expression changes in
mRNA encoding molecules within three overlapping death
receptor signaling categories were noted. In common, the three
categories implicated the Tumor Necrosis Factor Superfamily
member 6 (FAS) receptor or its putative ligand, Tumor Necrosis
Factor (ligand) Superfamily, member 13 (TNFSF13) [49] and the
down-stream cytoplasmic BH3 interacting domain death agonist
(BID). In the second stage of this study, we sought to confirm by
quantitative real time PCR (qRT-PCR) the altered mRNA levels
in cell-death genes in the DLPFC SMRI Array Collection. We
then carried out a replication study in an independent DLPFC
tissue collection from the Australian Tissue Resource Collection
(TRC) using qRT-PCR. The DLPFC SMRI Array Collection
included a bipolar disorder group enabling investigation of
diagnostic specificity of gene expression changes. Additionally,
we measured TNFSF13, the FAS receptor and BID mRNA levels
in the orbital frontal cortex (OFC) to assess regional specificity. We
next examined the relationships between mRNA levels of
TNFSF13 and markers of known neuropathology, i.e. expression
levels of interneuron (parvalbumin, somatostatin) and dendritic
spine (PPP1R9B and DLG4) mRNAs in the TRC collection.
Analysis of demographic variables and gene expression revealed a
large and significant negative correlation between tissue pH and
TNFSF13 expression. Since steady state levels of most transcripts
are typically decreased with lower tissue pH [50,51], the negative
correlation with TNFSF13 and pH was unexpected and suggested
that an active process of gene induction might be occurring in the
brain during low pH conditions. We therefore supplemented our
postmortem findings by performing two in vitro cell culture studies
to investigate experimentally the relationship between intracellular
pH and TNFSF13.
Results
Pathway analysis of the SMRI Array database
Seventeen apoptotic pathways of potential interest were
identified (see Table S1). Nine of these pathways had altered
expression of at least 1 gene. When a heat map ranking pathways
by GO term enrichment was consulted, we noted significant
differences in death receptor signaling pathways, FAS receptor,
death receptor 3 and death receptor 4/5. Within these death
receptor signaling pathways, 6 molecules (Table S1) had altered
expression in the DLPFC of patients with schizophrenia. Five of
these, TNFSF13 ligand (1.10 fold increase, p=0.0114), FAS
receptor (1.05 fold increase, p=0.0014), CFLAR (1.05 fold
increase, p=0.0343), BID (21.05 fold decrease, p=0.0288) and
Lamin A/C (1.07 fold increase, p=0.0001), were selected for
further analysis as these death molecules interact with each other
(outlined in Figure 1).
qRT-PCR analysis of TNFSF13-FAS receptor pathway
genes in the DLPFC
We used qRT-PCR with TaqMan probes designed to capture
all known expressed variants of the selected genes (pan, Table 1) to
confirm and replicate the changes observed by others using
microarray analysis in the SMRI Array collection of DLPFC
tissue. Initial qRT-PCR pilot experiments indicated that Lamin
A/C was expressed at very low levels in the DLPFC. We therefore
present results for four apoptotic pathway transcripts, describing
the results obtained for the DLPFC using the SMRI collection, the
TRC collection and the combined collections for each transcript in
turn. Combining the collections was considered useful as the
distribution of the data was better appreciated, more accurate
effect sizes could be calculated, and because it was justified on the
grounds of comparability of means and variance of expression
data.
We found that the expression of TNFSF13 mRNA in the
DLPFC was significantly increased in patients with schizophrenia
in both the SMRI (Figure S1, panel A, U=442.00, p=0.048 one-
tailed) and the NSW TRC (Figure S1, panel B, U=463.00,
p=0.0125 one-tailed) collections. In the combined collections
TNFSF13 mRNA was increased by 27% in patients with
schizophrenia relative to unaffected controls (Figure 2A:
U=1824.00, p=0.003 one-tailed, effect size r=0.23). While
individuals in both the control and schizophrenia group could
express elevated TNFSF13 mRNA, in the combined collection we
noted that more patients with schizophrenia fell into the high
expression range as illustrated by frequency distribution plots (see
red arrows in Figure 2B). This was significant when high
TNFSF13 expression was defined as 2-deltadelta Ct values greater
than the median plus 1.25 times the interquartile range for the
unaffected control group (.1.5787: x2(1)=4.931, p=0.026, two-
tailed). On average the mean of high TNFSF13 expressors in the
control group (3.05360.5615) were 5 standard deviations away
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normal distribution (0.891960.4308: D(62)=0.107, p=0.073).
Patients with schizophrenia were 2.47 times more likely to have
high TNFSF13 expression than unaffected controls. There was no
evidence of a changed expression of TNFSF13 mRNA in the
bipolar group relative to unaffected controls in the DLPFC
(Figure 3A: U=457.00, p=0.464 two-tailed, effect size r=0.09).
The group-wise expression of FAS receptor was not statistically
significantly increased in patients with schizophrenia in the SMRI
collection (Figure S1, panel C, U=501.00, p=0.174 one-tailed) or
the NSW TRC collection (Figure S1, panel D, U=554.00,
p=0.145 one-tailed), or within the combined DLPFC collections
(Figure 2C, U=2105.00, p=0.08 one-tailed, effect size r=0.12).
However, we once again noted that more patients with
schizophrenia fell in the high expression range (red arrows in
Figure 2D). This was significant when high FAS receptor
expression was defined as 2-deltadelta Ct values greater than the
median plus 1.25 times the interquartile range for the unaffected
control group (.1.661: x2(1)=4.875, p=0.027, two-tailed, effect
size r=0.19). On average the mean of high FAS receptor mRNA
expressors in the control group (1.81160.585) were 5 standard
deviations away from the mean of those FAS receptor mRNA
values that formed a normal distribution (0.75860.193:
D(48)=0.126, p=0.056). Patients with schizophrenia were 2.61
times more likely to have high FAS receptor expression than
unaffected controls. FAS receptor expression in the bipolar
disorder group was not significantly different to that of unaffected
controls (Figure 3B: U=459.00, p=0.62 two-tailed, effect size
r=0.06).
CFLARpan expression was not significantly changed within the
schizophrenia group in the SMRI or NSW TRC collections
(Figure S1, panels E–F), nor in the combined collections
(U=2174.00, p=0.101 one-tailed, Figure 2E, effect size
r=0.11). CFLAR is expressed as several different protein forming
splice variants [52], the most important ones being CFLARshort
and CFLARlong, which have opposing effects on caspase-8 activity.
While it is not possible to specifically target CFLARshort transcripts
using qRT-PCR, we determined expression of CFLARlong and
found it not to be differentially expressed in the schizophrenia
group in the SMRI or NSW TRC collections (Figure S1, panels
G–H), nor in the combined collections (U=2407.00, p=0.323
one-tailed, Figure 2F, effect size r=0.04). Similarly, there were no
group differences between patients with bipolar disorder and
unaffected controls (Figure 3C, D) in CFLARpan (U=413.00,
p=0.186 two-tailed, effect size r=0.09) or CFLARlong expression
(U=457.00, p=0.0.464 two-tailed, effect size r=0.16).
The expression of the pro-apoptotic gene, BID was significantly
decreased in DLPFC from the SMRI collection (t(66)=2.381,
p=0.01 one-tailed, Figure S1, panel I), but not in the NSW TRC
(t(71)=1.607, p=0.057 one-tailed, Figure S1, panel J). In the
combined collection, the decreased expression of BID in tissue
from patients with schizophrenia was statistically significant
(Figure 2G, H: t(139)=2.656, p=0.005 one-tailed, effect size
r=0.22). Patients with bipolar disorder also had reduced
expression of BID (Figure 3E: t(61)=2.74, p=0.005 one-tailed,
effect size r=0.33).
qRT-PCR analysis of TNFSF13-FAS receptor pathway
genes in the OFC
We observed no significant effect of diagnosis on mRNA levels
of TNFSF13 (x
2(2)=2.38, p=0.304), FAS receptor (x
2(2)=2.15,
p=0.342), or BID (F(2)=1.675, p=0.193) in the OFC of the
SMRI collection (Figure 4A, B, C). The effect size between control
and schizophrenia cases for TNFSF13 in the OFC (r=0.10)
suggests that this negative finding is not simply attributable to the
smaller sample size within the SMRI collection relative to that of
the combined collections. The effect size for BID between controls
and schizophrenia cases (r=0.32) and bipolar disorder cases
(r=0.34) indicated that diagnosis accounted for over 10% of the
variance in gene expression within either diagnostic group.
TNFSF13 expression in the DLPFC and its relationship to
pyramidal cell and interneuron markers
We measured expression of two dendritic spine mRNAs in the
TRC collection, but failed to observe any altered transcript levels
in patients with schizophrenia relative to controls for PPP1R9B
(U=609.00, p=0.529) or DLG4 (t(71)=21.139, p=0.258). The
Figure 1. FAS receptor pathway in peripheral cells [76]. The
membrane FAS-R (blue) forms a trimer upon ligand binding (TNFSF13,
red). The adaptor molecule FADD (green) then binds to the death
domain of FAS-R through its own death domain. The amino terminus of
FADD facilitates binding to caspase-8 (maroon oval). Caspase-8 self-
activates through proteolytic cleavage into active caspase subunits,
which can cleave other effector caspases (3, 6, 9), eventually leading to
DNA degradation, membrane blebbing, and other hallmarks of
apoptosis. In most cell types (Type II), caspase-8 catalyzes the cleavage
of the pro-apoptotic BH3-only protein BID (orange) into its truncated
form, tBID. tBID engages anti-apoptotic members of the family (e.g.
BCL-2), allowing pro-apoptotic members (e.g. BAX) to translocate to the
outer mitochondrial membrane, thus permeabilizing the membrane
and facilitating release of pro-apoptotic proteins such as cytochrome c
(tan). Cytochrome c release reinforces the cellular apoptotic drive
through the intrinsic apoptotic pathway. Death receptors 4/5 (TNFSF10)
appear to have identical intracellular pathway signaling to FAS receptor
[76].
doi:10.1371/journal.pone.0035511.g001
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been reported to be reduced in patients with schizophrenia in the
TRC collection [41]. To explore the relationship between
TNFSF13 expression and markers of pyramidal cell spines
(PPP1R9B and DLG4) and interneuron subtypes (parvalbumin
and somatostatin), we calculated the observed variances between
these measures (Table 2). This revealed significant negative
correlations between TNFSF13 mRNA and parvalbumin and
somatostatin mRNAs. TNSFSF13 was positively correlated with
PPP1R9B, but there was only a weak relationship with DLG4
mRNA, where TNFSF13 accounted for less than 10% of the
variance. As pH correlated negatively with the expression of
TNFSF13 mRNA, we next carried out regression analyses
including pH to determine its contribution to the observed
association between TNFSF13 and spine and interneuron
markers. We found that in the control group pH accounted for
38% of the variance of somatostatin, and 11% of DLG4. pH
accounted for significant amounts of variance in parvalbumin
(12%), somatostatin (36%), DLG4 (13%) and PPP1R9B (11%) in
the schizophrenia group. Over and above the effect of pH,
TNFSF13 expression accounted for significant variance in
PPP1R9B (24–36%) in both groups, however TNFSF13 mRNA
did not account for any additional variance in the two interneuron
mRNA measures.
Our analysis of the relationship of TNFSF13 pathway gene
expressions in the DLPFC with demographic and clinical variables
(Table 3) revealed significant negative correlations with tissue pH.
Tissue pH also appeared to play a significant role in the
relationship between TNFSF13 and markers of interneuron
health. This led us to focus our next set of studies on the role of
tissue pH in TNFSF13 expression.
Cell culture studies of the relationship between TNFSF13
and FAS receptor expression and pH
We tested experimentally whether lowered intracellular pH
would increase TNFSF13 mRNA levels in cultured glioblastoma
cells, U-87 MG. Because statistical correlations in postmortem
tissue do not indicate directional cause, we also determined if
higher levels of TNFSF13 could lead to lower pH in U-87 MG cell
cultures.
In the first study, we lowered intracellular pH by exposing cells
to nigericin and potassium phosphate buffers and then determined
expression of TNFSF13 and FAS receptor mRNAs 0.5, 3, 12 and
24 hours later. In contrast to our hypothesis, we found that cells
with reduced pH (pH 6.4 and 6.9) had reduced TNFSF13 mRNA
expression relative to cells with physiological pH (F(2,23)=4.464,
p=0.023 two-way ANOVA, post-hoc tests p,0.05 for both
pH 6.4 and 6.9, Figure 5A). While a similar expression pattern
was observed for the FAS receptor (Figure 5B), the two-way
ANOVA did not support a significant effect of pH on this
transcript (F(3,23)=1.616, p=0.220). There was a significant
effect of time on expression of both transcripts (TNFSF13:
F(3,23)=4.937, p=0.009; FAS receptor: F(3,23)=41.263,
p,0.001) attributable to the expressions at the 0.5 hour time
point being greater than the 3, 12, and 24 hour time points (post-
hoc tests p,0.05). Although exposure to nigericin caused an early
increase in TNFSF13 and FAS receptor expression (0.5 hour time
point) this increase occurred irrespective of the culture media pH.
In the second study, we examined whether increased levels of
TNFSF13 ligand could lower intra-cellular pH. This was done by
adding TNFSF13 to glioblastoma cell cultures (U-87 MG:
Figure 5C). Again, contrary to our hypothesis, we found that
intracellular pH was significantly increased relative to vehicle-
treated cells 12, 24 and 48 hours following exposure to TNFSF13
(t(5)=5.180–10.38, p,0.01 for all time points, one-sample t-test
uncorrected for multiple comparisons). The highest pH was
measured 24 hours following TNFSF13 exposure with evidence of
a return towards baseline at 48 hours.
Discussion
The current study is the first to specifically report, confirm, and
replicate in an independent postmortem tissue collection, an
increase in mRNA transcript levels of the tumor necrosis factor
receptor ligand, TNFSF13, in the DLPFC of patients with
schizophrenia. The replication of this finding in an independent
tissue collection (NSW TRC) and the magnitude of the TNFSF13
expression change suggest the observed increase is unlikely to be
due to Type I error. The study is also the first study to provide
direct evidence of a relationship between altered apoptotic
pathway signaling and putative neuronal markers of neuropathol-
Table 1. Genes analyzed with ABI Taqman Gene Expression assay part numbers.
Gene symbol Gene name Taqman assay
TNFSF13 Tumor necrosis factor (ligand) superfamily, member 13 Hs00182565_m1
FAS Fas (TNF receptor superfamily, member 6) Hs00236330_m1
CFLAR CASP8 and FADD-like apoptosis regulator Hs01116280_m1
CFLAR CASP8 and FADD-like apoptosis regulator Hs00153439_m1
BID BH3 interacting domain death agonist Hs00609632_m1
Lamin A/C Lamin A/C Hs00153462_m1
DLG4 discs, large homolog 4 Hs00176354_m1
PPP1R9B protein phosphatase 1, regulatory (inhibitor) subunit 9B Hs00261636_m1
SST
1 Somatostatin Hs00356144_m1
PV
1 Parvalbumin Hs00161045_m1
ACTB b-Actin Hs99999903_m1
TBP TATA box binding protein Hs00427620_m1
UBC Ubiquitin C Hs00824723_m1
1Data previously published by Fung et al. [41].
doi:10.1371/journal.pone.0035511.t001
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35511Figure 2. Gene expression levels of TNFSF13-FAS receptor pathway genes of interest relative to three housekeeping genes in
dorsolateral prefrontal cortex from patients with schizophrenia. cDNA samples obtained from the combined SMRI and NSW TRC collections
from individuals with schizophrenia and unaffected controls were subjected to qRT-PCR. Expressions of TNFSF13 (A), FAS receptor (C), CFLARpan (E),
CFLARlong (F) and BID (G) relative to three housekeeping genes (b-actin, TATA box binding protein and ubiquitin C) were calculated using the
deltadelta Ct method. Horizontal lines indicate the population median, except for panel (G) where they indicate the mean as those data were
normally distributed. Frequency distributions for TNFSF13, FAS receptor and BID are displayed in panels (B), (D), and (H). ** p,0.01.
doi:10.1371/journal.pone.0035511.g002
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evident in the OFC of patients with schizophrenia suggesting that
increased TNFSF13 expression in the DLPFC may not be a non-
specific consequence of severe mental illness [3]. Whilst other
studies have observed increased TNFSF13 expression in reactive
astrocytes in multiple sclerosis [53] and in cells surrounding tumor
tissue [54], the absence of TNFSF13 expression changes in
patients with bipolar disorder suggests at least a degree of
diagnostic specificity for the TNFSF13 mRNA change between
the two psychiatric groups. The robust abnormality in TNFSF13
mRNA transcript levels in the DLPFC warrants confirmation at
the protein level as well as further study of factors contributing to
the increased TNFSF13 expression in patients with schizophrenia.
TNFSF13 has been shown to bind to four tumor necrosis factor
receptor family members [49,55]. However, the expressions of
three of these receptors are very limited or entirely absent in the
CNS [55,56] and were therefore not pursued in the current study.
The fourth receptor, FAS, was originally identified as a
lymphocyte receptor but is also widely expressed in the CNS
[57]. Consistent with TNFSF13 activating the FAS receptor
pathway, we found that TNFSF13 transcript levels correlated
strongly with FAS receptor mRNA expression and that patients
with schizophrenia were more likely to have high FAS receptor
expression (39%) in the DLPFC as compared to controls (15%
with increased FAS receptor).
Ligand binding to FAS receptor typically results in the
formation of a death-inducing signaling complex, of which
CFLAR is an important modulating component [58]. Our qRT-
PCR investigation did not confirm or replicate the increased
CFLAR expression observed in schizophrenia tissue by micro-
array. Inability to confirm array results may be attributable to low
transcript levels of CFLAR or failure of the qRT-PCR probe to
capture the same transcript(s) as the microarrays [59]. Despite
CFLAR transcripts levels being relatively low in the CNS, we
found CFLAR probes amplified robustly at the same cDNA
concentration as TNFSF13 and FAS receptor probes. This
suggests lack of qRT-PCR confirmation of array results for
CFLAR in our study is most likely attributable to differences in the
transcripts captured by the different assays. Pinpointing differences
in transcripts captured by array compared to our qRT-PCR will
take further transcript characterization studies.
Increased TNFSF13 expression suggests increased apoptotic
signaling in our schizophrenia group. However, as predicted by
the results in the SMRI array database we found decreased
transcripts levels of the pro-apoptotic BID in patients with
schizophrenia. Decreased gene expression could be a compensa-
tory change to counteract detrimental effects of increased
apoptotic signaling, however, the absence of a negative correlation
between TNFSF13 mRNA expression and BID mRNA does not
support a direct relationship between the two transcripts.
Decreased BID transcript levels in the DLPFC were also observed
in patient with bipolar disorder and thus not specific to just one
psychotic disorder. Because expression of other BH3-genes, such
Figure 3. Gene expression levels of TNFSF13-FAS receptor
pathway genes of interest relative to three housekeeping
genes in dorsolateral prefrontal cortex from patients with
bipolar disorder. cDNA samples obtained from the SMRI collection
from individuals with bipolar disorder and unaffected controls were
subjected to qRT-PCR. Expressions of TNFSF13 (A), FAS receptor (B), BID
(C), CFLARpan (D), and CFLARlong (E) relative to three housekeeping
genes (b-actin, TATA box binding protein and ubiquitin C) were
calculated using the deltadelta Ct method. Horizontal lines indicate the
population median, except for panel (E) where they indicate the mean
as those data were normally distributed. * p,0.05.
doi:10.1371/journal.pone.0035511.g003
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different antidepressants and mood stabilizers [60] commonly
prescribed to both patients with schizophrenia and bipolar
disorder, we explored but did not find support for antidepressant
medications playing a role in the decreased expression of BID in
our patient groups. There were more patients who were smokers
in the schizophrenia groups than in the unaffected control group.
We found that smoking might interact with disease-specific factors
in the schizophrenia group and contribute to decreased BID
expression, a phenomena described previously for other transcripts
[61].
In order to put changes in TNFSF13 mRNA levels in the
context of known schizophrenia neuropathology, we explored the
relationship between levels of TNFSF13 mRNA and transcript
levels of interneuron markers, somatostatin and parvalbumin, as
well as spine markers, DLG4 and PPP1R9B. Our regression
analysis results are consistent with TNFSF13 contributing to the
established interneuron deficits in schizophrenia. As parvalbumin
mRNA levels in schizophrenia tissue have been observed to
correlate positively with pH in several studies [36,41,62,63] and
TNFSF13 expression correlated negatively with tissue pH in the
current study, this means that as tissue pH is lowered, parvalbumin
mRNA decreases but TNFSF13 mRNA increases. Our observa-
tion that variance in tissue pH could account for the relationship
between interneuron markers and TNFSF13 mRNA is significant
because it suggests that an active process (upregulation of
TNFSF13) related to tissue pH may be a mediating factor of the
interneuron deficit. While we did not observe any effect of
diagnostic group on the expression levels of either spine marker,
DLG4 and PPP1R9B, this was not entirely unexpected as previous
reports have also failed to find change in these mRNAs in
schizophrenia [64,65]. This suggests that DLG4 and PPP1R9B
mRNA levels may not closely reflect the morphological changes
observed in dendritic spines in patients with schizophrenia. Given
that changes in spine marker mRNA may be more prevalent in
some cases as compared to others, we asked if levels of spine
markers relate to the observed changes in TNFSF13 expression by
regression analysis. We hypothesized that increased TNFSF13
would be related to decreased spine markers. Surprisingly, our
result suggests that increased TNFSF13 expression may contribute
to increased PPP1R9B expression and that this effect is
independent of pH. However, our cell culture results indicate
that ligands such as TNFSF13 can transiently increase pH not
decrease it as found in human brain tissue. Perhaps in vivo
manipulation of TNFSF13 in brain may better capture the
interplay between different cell types. Our experimental cell
culture studies did suggest that changes in TNFSF13 and pH may
not be directly linked, but that since they occur in the context of
brain tissue may both represent reactions to another upstream
event.
The negative correlation between TNFSF13 and interneuron
markers and the positive correlation with spine markers could
suggest a pleiotropic effect of TNFSF13 in the CNS. Consistent
with the notion that TNFSF13 may lead to growth inducing events
in the dendritic spine rather than solely cell-death related events,
FAS receptor activation has been observed to induce stem cell
proliferation, differentiation [66] and dendritic branching [67] in
the CNS. Our data support the possibility that FAS receptor
activation by TNFSF13 in adult cortex leads to activation of
alternate intracellular signaling pathways, which have opposing
effects on interneurons and pyramidal cells. Another cytokine,
interleukin-1b, has been shown to activate excitatory pyramidal
neurons and inhibit GABA neurons, leading to an overall increase
in excitatory tone and seizure activity [68]. This is consistent with
recent work by Behrens and colleagues [18,69] demonstrating that
treatment with the NMDA antagonist, ketamine, results in
increased interleukin-6 production, which in turn leads to reduced
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
Figure 4. Gene expression levels of TNFSF13, FAS receptor and
BID relative to three housekeeping genes in OFC from patients
with schizophrenia, patients with bipolar disorder and unaf-
fected controls. cDNA samples from individuals with schizophrenia,
bipolar disorder and unaffected controls were subjected to qRT-PCR.
Expressions of TNFSF13 (A), FAS receptor (B) and BID (C) relative to
three housekeeping genes (b-actin, TATA box binding protein and
ubiquitin C) were calculated using the deltadelta Ct method. Horizontal
lines indicate the population median, except for panel (C) where they
indicate the mean as those data were normally distributed.
doi:10.1371/journal.pone.0035511.g004
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observed in patients with schizophrenia. Furthermore, increased
activity of NADPH oxidase has previously been shown to result in
decreased intracellular pH [70], a proxy for levels of oxidative
stress in the measured tissue [71]. It may therefore be that
TNFSF13 acts not as an apoptosis inducer, but in the role of a
cytokine able to differentially modulate neuron physiology in
response to perturbations in the adult CNS. An alternative
explanation for the positive correlation beween TNFSF13 and
PPP1R9B is that PPP1R9B mRNA expression levels may not
directly reflect spine number, but rather spine modifyability.
Indeed, young rodents lacking spinophilin (PPP1R9B) have
increased spine numbers suggesting more stability but less
plasticity [72]. Therefore, the correlation between increased
TNFSF13 expression with increased PPP1R9B that we find might
reflect less stability of synaptic spines, which in the context of
schizophrenia could be detrimental to spine density.
Our study of gene expression changes was limited by restricting
it to qRT-PCR measures of mRNA transcripts only. Whether
changes observed at the transcript level are reflected in changes in
protein levels require further investigation. By focusing on
transcripts that had showed expression change by array analysis,
we also limited our study in scope. It is possible that other
transcripts in the cell death pathway have altered expression levels.
However, the main effector molecules in the FAS receptor
pathway are caspases, proteases which are regulated at the level
of protein cleavage, and therefore better studied at the protein
level. Future investigations of the cell death pathway in
Table 3. Relationship of gene expression in the DLPFC with demographic and clinical variables.
TNFSF13 FAS receptor CFLARpan CFLARlong BID
Age n.s. n.s. r=0.331, p=0.008 n.s. n.s.
Sex n.s. n.s. n.s. n.s. n.s.
Brain hemisphere n.s. n.s. n.s. U=0.409, p=0.007
a n.s.
Postmortem interval r=20.173, p=0.023 r=20.247, p=0.001 n.s. n.s. n.s.
pH r=20.484, p,0.001 r=20.404, p,0.001 r=20.410, p,0.001 r=20.385, p,0.001 n.s.
Smoking n.s. n.s. n.s. n.s. t(55)=2.17, p=0.035
b
Age at onset n.s. n.s. n.s. n.s. n.s.
Duration of illness n.s. n.s. r=0.280, p=0.007 n.s. n.s.
Lifetime antipsychotic use r=0.289, p=0.014 n.s. r=0.238, p=0.044 n.s. n.s.
Antidepressant n.s. n.s. n.s. n.s. n.s.
Death by suicide U=268, p=0.0027 n.s. n.s. n.s. n.s.
All correlations listed are Spearman’s.
n.s. Not statistically significant.
aIncreased in right hemisphere.
bDecreased in patients with schizophrenia who smoke.
doi:10.1371/journal.pone.0035511.t003
Table 2. Variance (R
2) in parvalbumin, somatostatin, PPP1R9B and DLG4 mRNA transcript levels accounted for by TNFSF13
expression and tissue pH in the NSW TRC collection.
Unaffected control group Schizophrenia group
TNFSF13 pH D TNFSF13 TNFSF13 pH D TNFSF13
Interneurons
Parvalbumin R
2 .170* .051 .058 .072 .123* .003
b 2.413* .225 2.269 .350*
Somatostatin R
2 .293** .383*** .006 .247** .364*** .020
b 2.541*** .619*** 2.497** .604***
Spines
PPP1R9B R
2 .169* .085 .244** .451*** .112* .358***
b .411* 2.262 .672*** 2.335*
DLG4 R
2 .063 .111* .003 .002 .127* .126*
b 2.251 .333* .049 .357*
D TNFSF13: Change in R
2 accounted for by TNFSF13 when pH controlled for.
b Standardized coefficient.
*p,0.05;
**p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0035511.t002
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levels in addition to the TNFSF13 ligand and FAS receptor.
In conclusion, a broad-spectrum microarray inquiry revealed a
selective alteration in the gene expression of molecules related to
the TNFSF13 cell death pathway. The microarray-identified
alteration in TNFSF13 mRNA was confirmed using qRT-PCR
and replicated in an independent brain tissue collection. The
alteration in TNFSF13 gene expression showed relative disease
specificity, as it was observed in the schizophrenia and not the
bipolar disorder cases and showed relative brain region specificity
in schizophrenia, as it was observed in the DLPFC and not in the
OFC. Of note, we found TNFSF13 mRNA expression in the
DLPFC was significantly positively correlated with the spine
marker, PPP1R9B (spinophilin) and significantly negatively
correlated with mRNA expression of interneuron markers,
parvalbumin and somatostatin, the latter being influenced by
tissue pH. One explanation for these inverse relationships with
inhibitory and excitatory neuronal markers is that the cytokine
actions rather than the apoptotic actions of TNFSF13 are mainly
contributing to the observed pathology in schizophrenia. We
propose a model where TNFSF13, like the interleukins, can
increase excitatory pyramidal neuron activity, indexed by
increased PPP1R9B, and decrease interneuron health, indexed
by tissue pH-dependent decreased expression of interneuron
markers, parvalbumin and somatostatin.
Materials and Methods
In silico pathway analysis of the existing SMRI Array
database
To identify candidate cell death pathways, the existing SMRI
Array database was searched for the keywords ‘‘apoptosis’’ and
‘‘death’’. The SMRI Array database consists of results of 6
microarray studies of 35 people with schizophrenia, 35 people with
bipolar illness and 35 controls (Array collection) and 6 microarray
studies of 15 people with schizophrenia, 15 people with bipolar
illness, 15 people with depression and 15 controls (Consortium
collection) [48]. While studies mostly focus on prefrontal cortex
(BA8/9/10/46), it also includes two studies of the cerebellum. The
database reports the fold change and significance for the
Consortium collection and the Array collection separately and
combined. We relied on the combined data for determining
significantly changed gene expressions. The fold change reported
in the Array database did not control for potentially confounding
factors such as age and tissue pH, though these factors were
independently explored for each transcript. For a detailed
decription of how the cross-study analysis was performed, see
Higgs et al. [48]. A heat map ranking pathways by GO term
enrichment was also consulted. These database resources are
available to researchers at www.stanleygenomics.org.
Human postmortem tissue studies
Ethics Statement. All research was approved by and
conducted under the guidelines of the Human Research Ethics
Committee at the University of New South Wales (HREC 07261).
Subjects. For the DLPFC, samples from two postmortem
brain tissue collections were analysed. The Australian TRC
collection [73] consisted of 37 patients with schizophrenia/
schizoaffective disorder and 37 unaffected controls. The SMRI
Array collection consisted of 35 patients with schizophrenia, 31
patients with bipolar disorder and 34 unaffected controls. RNA
extracted from the lateral OFC was obtained from the same
subjects within the SMRI Array collection that provided RNA
from the DLPFC (one case in the schizophrenia group was
excluded because of technical problems). RNA obtained from the
SMRI tissues, Maryland, USA (http://www.stanleyresearch.org/
dnn/BrainResearchCollection/ArrayCollection/tabid/89/
Default.aspx) was transported to Sydney, Australia on dry ice.
Demographic and clinical variables for the SMRI and TRC
collections of tissue, separately and combined, are detailed in
Tables S2 and S3 and Table 4. Patient and control groups did not
differ according to age, sex, brain hemisphere or postmortem
delay, except for a significantly greater number of females in the
Figure 5. The effect of TNFSF13 exposure on intracellular pH,
and of decreased intracellular pH on TNFSF13 and FAS
receptor gene expression. Intracellular pH of U-87 MG cells was
artificially decreased using nigericin and phosphate buffer to pH 6.4, 6.9
and 7.3 for 0.5, 3, 12 or 24 hours and transcript levels of the TNFSF13 (A)
or FAS receptor (B) genes measured by qRT-PCR. Expression levels were
calculated relative to three housekeeping genes (b-actin, TATA box
binding protein and ubiquitin C) using the deltadelta Ct method.
aTranscript levels at the 0.5 hours time point were significantly greater
than at all other time points,
bDecreasing pH significantly suppressed
transcript levels of TNFSF13,
cThere was no significant effect of pH on
FAS receptor transcripts. U-87 MG glioblastoma cell cultures were
treated with TNFSF13 (1 pg or 100 pg TNFSF13/microliter of culture
media) for up to 48 hours and the intracellular pH determined (C).
*p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0035511.g005
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the schizophrenia and bipolar groups had significantly lower tissue
pH than the unaffected control group. The schizophrenia groups
in both the SMRI and NSW TRC collections had a significantly
greater proportion of patients who smoked at the time of death,
and who died from suicide.
RNA extraction and qRT-PCR. For both collections, RNA
extraction was carried out using TRIzol Reagent (Invitrogen Life
Sciences, Melbourne, VIC, Australia). cDNA was generated using
a SuperScript First-Strand Synthesis kit (Invitrogen, Carlsbad, CA,
USA) as described in Weickert et al. [73].
Expression levels of 12 transcripts (see Table 1) were used in this
study, including 5 apoptosis-related transcripts: TNFSF13; FAS
receptor; BID; two transcript variants (pan and long) of CASP8
and FADD-like apoptosis regulator (CFLAR); 2 spine marker
mRNAs: discs, large homolog 4 (DLG4, also known as PSD-95);
and protein phosphatase 1, regulatory (inhibitor) subunit 9B
(PPP1R9B, also known as spinophilin); 2 previously measured
mRNAs for inhibitory markers parvalbumin and somatostatin
[41]; and 3 housekeeper genes: b-actin; TATA box binding
protein; and ubiquitin C. These were measured by qRT-PCR
using published methods [73]. Samples were measured in triplicate
and measurement outliers removed. The relative quantities of
mRNA levels were calculated using the deltadelta Ct method,
normalizing to the geomean Ct levels of housekeeping genes. The
amplification efficiency for the three housekeeping genes ranged
from 64 to 89%, whereas the amplification efficiency for test genes
ranged from 60 to 104%.
Cell culture studies
We found an unexpected strong negative correlation between
gene expression of TNFSF13 and tissue pH and explored whether
a low pH caused increased TNFSF13 or if increased TNFSF13
could cause decreased pH. Since TNFSF13 and FAS receptor can
be synthesized in glia, the U-87 MG human glioblastoma (ACTT
Catalogue Number HTB-14) cell line was cultured under standard
conditions (37uC, 5% CO2) in Dulbecco’s modified Eagle media
with high glucose supplemented with 10% fetal bovine serum.
Cells were seeded in culture plates at 1.25610
6 cells/mL 24 hours
prior to commencement of assays.
Effect of reduced intra-cellular pH on TNFSF13
expression. U-87 MG cells were plated into 12-well plates.
On the day of the assay, 50% of the culture media was replaced
with buffers containing 120 mM potassium phosphate, 20 mM
sodium chloride at pH 7.3, 6.9 and 6.4. These buffers also
contained 1 mM nigericin (0.5 mM final concentration; Invitrogen
Life Sciences, Australia) which rapidly decreases the intracellular
pH to that of the culture media. Thirty minutes, 3, 12 and
24 hours later, triplicate cultures at each pH were washed twice in
PBS and RNA extracted using TRIzol reagent according to the
manufacturer’s instructions. Transcript levels of TNFSF13 and
FAS receptor and 3 housekeeper genes – b-actin, TATA box
binding protein and ubiquitin C – were determined by qRT-PCR
as described above.
Effect of TNFSF13 on intra-cellular pH. U-87 MG cells
were plated into 96-well plates. Human recombinant TNFSF13
(Catalogue Number 884-AP, RD Systems) was added (in 50%
fresh media) at final concentrations of 0, 1 and 100 ng TNFSF13/
mL media 48, 24 and 12 hours prior to pH determination. At time
zero (48 hours after assay commencement), all wells were quickly
washed in 37uC PBS, pH 7.4 followed by incubation for
30 minutes at 37uC with 10 mM2 9,79-bis-(2-carboxyethyl)-5-
(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF-AM:
Invitrogen Life Sciences, Australia) in PBS. Wells were then
washed once with fresh, cold PBS and the 96-well culture plate
placed on ice. Following 488 nm excitation, the 525/610
fluorescence ratio, which is indicative of intracellular pH [74],
was determined using a plate reader (POLARstar, BMG Labtech).
Results are presented as percent change in 525/610 ratio from
that of control cells.
Statistical analysis
Statistical analyses were conducted using SPSS version 17.0.
Population outliers were determined using the Grubb’s test. Data
were analyzed using parametric and non-parametric tests as
appropriate to determine group differences in gene expression
levels, and to examine if gender, hemisphere, smoking status,
antidepressant medication or peri-mortem factors were related to
gene expression levels. We correlated gene expression levels for
each diagnostic group with continuous demographic (age, pH,
Table 4. Demographic and clinical variables of the combined SMRI and NSW TRC collection.
Control Schizophrenia Statistics
N7 1 7 2
Race (A/B/C/D)
a 70/1/0 70/1/1
Age (years) 47.6612.2 47.1612.5 t(141)=0.274, p=0.785
Sex (male/female) 55/16 50/22 X
2(1)=1.179, p=0.278
Hemisphere (left/right) 30/41 37/35 X
2(1)=1.198, p=0.274
Postmortem delay 27.04612.15 29.89614.63 t(141)=21.267, p=0.207
Tissue pH 6.6460.28 6.5560.28 t(141)=1.932, p=0.055
Death by suicide (yes/no) 0/71 15/57 X
2(1)=16.525, p=0.000
Smoking status (yes/no) 18/21 46/11 X
2(1)=12.437, p=0.000
Duration of illness (years) - 24.54612.50
Age of onset (years) - 22.5366.15
Medication (lifetime chlorpromazine) - 6,129,70066,893,220
The combined SMRI and NSW TRC collections were utilized for analysis of gene expression in the DLPFC only. Data are provided as means 6 the standard deviation or
number of individuals in each category.
aA/B/C/D: European/Asian/Hispanic.
doi:10.1371/journal.pone.0035511.t004
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chlorpromazine equivalent dose, last reported chlorpromazine
equivalent dose, lifetime equivalent chlorpromazine dose) vari-
ables. Statistical significance was set at p#0.05 with tests being
one-tailed (when measuring gene expression changes predicted by
the array results) or two-tailed (when assessing unpredicted
relationships). Effect sizes were calculated for diagnostic effects
according to Field [75]. High expression of TNFSF13 and FAS
receptor was defined as deltadelta Ct values greater than the
median plus 1.25 times the interquartile range for the unaffected
control group. We determined the values for the normal
distribution of TNFSF13 and FAS receptor mRNA expression
by reiterative step-wise removal of the highest expressor and
testing of normality using the Kolmogorov-Smirnow statistics until
such point where the significance value was greater than 0.05.
Linear regression was carried out with somatostatin, parvalbumin,
DLG4 or PPP1R9B transcript levels as the dependent variable,
specifying TNFSF13 alone or in combination with tissue pH as
independent variables.
Supporting Information
Figure S1 Gene expression levels of TNFSF13-FAS
receptor pathway genes of interest relative to three
housekeeping genes in dorsolateral prefrontal cortex
from patients with schizophrenia. cDNA samples obtained
from the SMRI (Panel A, C, E, G, I) and NSW TRC (Panel B, D,
F, H, J) collections from individuals with schizophrenia and
unaffected controls were subjected to qRT-PCR. Expressions of
TNFSF13 (A, B), FAS receptor (C, D), CFLARpan (E, F),
CFLARlong (G, H), and BID (I, J) relative to three housekeeping
genes (b-actin, TATA box binding protein and ubiquitin C) were
calculated using the deltadelta Ct method. Horizontal lines
indicate the population median, except for panel (E) where they
indicate the mean as those data were normally distributed. *
p,0.05.
(TIF)
Table S1 Pathway analysis of the SMRI Array database
identified 17 apoptotic pathways of potential interest.
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Table S2 Demographic and clinical variables of groups
included in the SMRI collection.
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Table S3 Demographic and clinical variables of groups
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